SUO Annual Meeting

Early findings from two phase 3 clinical trials support treatment options beyond surgery in NMIBC, with one expert suggesting a possible “paradigm shift” soon.

Enzalutamide plus leuprolide is effective in high-risk prostate cancer, “and you don’t have to sacrifice quality of life to get those benefits,” one author said.

Results of a real-world analysis point to key considerations for clinicians when initiating androgen deprivation therapy in patients with prostate cancer.

Phase 3 bladder cancer data will take center stage at the SUO Annual Meeting. Ensuring that urologic oncology fellowships remain relevant is also a top focus.

Early findings from two phase 3 clinical trials support treatment options beyond surgery in NMIBC, with one expert suggesting a possible “paradigm shift” soon.

Enzalutamide plus leuprolide is effective in high-risk prostate cancer, “and you don’t have to sacrifice quality of life to get those benefits,” one author said.

Phase 3 bladder cancer data will take center stage at the SUO Annual Meeting. Ensuring that urologic oncology fellowships remain relevant is also a top focus.

Results of a real-world analysis point to key considerations for clinicians when initiating androgen deprivation therapy in patients with prostate cancer.